Boston Scientific (NYSE:BSX) announced today that it invested $1.5 billion in transcatheter aortic valve replacement (TAVR) ...

The deal gives Boston Scientific a 34% equity stake in MiRus and an option to acquire its TAVR platform by making additional ...

ALL WOMEN reported alongside 3-year data from SMART ...

BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Ltd (ASX: AVR), a structural heart company developing DurAVR™ THV, a new class of TAVR and the world’s only balloon-expandable ...

May 18 (Reuters) - U.S. medical device maker Boston Scientific said on Monday it has invested $1.5 billion in privately held ...

EmStop, Inc., a cardiovascular medical device company, announced the initiation of the CAPTURE-2 Investigational Device Exemption (IDE) clinical trial in support of the company's mission to develop ...

Medtronic was found guilty this week of infringing a patent concerning transcatheter aortic valve replacement (TAVR) systems that was awarded to Colibri Heart Valve in 2014. In a lawsuit filed in a ...

Boston Scientific may acquire full ownership of MiRus’ TAVR business for an additional $3bn after achieving certain milestones.

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

The first day at the recently concluded Transcatheter Cardiovascular Therapies (TCT) meeting in Washington, D.C., was reportedly heavily focused on TAVR - transcatheter aortic valve replacement ...